LYNNTECH INC. — Department of Homeland Security SBIR Phase II: DHS211-011

Description

There is a continuing need for the development of new and innovative diagnostic technologies to inform and protect our nation against biological threat agents. These agents include pathogenic bacteria, viruses, and toxins. Early awareness of such threats equates to early response to minimize exposure and risk. Lynntech is developing a detection assay that can simultaneously detect multiple types of biological threat agents, namely bacteria, viruses, and toxins. Our detection system will provide a lightweight, power-free, rapid, sensitive, and specific means to detect and identify multiple biothreat agents. Validation of our system will include internal testing, as well as third-party, external testing - providing data regarding Reproducibility, Diagnostic Sensitivity, and Diagnostic Specificity.A major benefit associated with our biothreat detection system is its adaptability.Our system can be readily modified to detect an endless number of threat agents.In addition to established biological threat agents, our system can be adapted to detect new agents as they become part of this unprecedented biological warfare. Current market analyses suggest that the global biodefense market will reach $19B by 2024, enjoying a Compound Annual Growth Rate of 6.5%. Given the specifications and performance requirements (including price), we anticipate Lynntech's peptide-based lateral flow assay will partake in this market growth. Indeed, we believe that both government agencies (like DHS), as well as the general public, will be interested in our system.